Mounjaro vs Zepbound: Same Drug, Two Different Labels

Yes, Mounjaro and Zepbound are the same drug. Both contain tirzepatide, a once-weekly injectable made by Eli Lilly, and both come in the identical dose ladder of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Tirzepatide is a dual agonist, meaning it activates two gut-hormone receptors at once: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual action is what sets it apart from older single-receptor drugs like semaglutide.

The difference is branding and regulation. Mounjaro was approved by the FDA in May 2022 for type 2 diabetes. Zepbound was approved in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with a weight-related condition, and later for moderate-to-severe obstructive sleep apnea. Same molecule, same factory, two labels written for two different medical purposes. If you want a deeper look at how tirzepatide compares to its main rival, see our guide on [tirzepatide vs semaglutide](/blog/tirzepatide-vs-semaglutide-comparison-2026).

Eli Lilly sells tirzepatide under two names because the FDA approves drugs for specific indications, the medical conditions a drug is officially cleared to treat. A single brand can only carry the indications it was studied and approved for. By creating Zepbound as a separate brand for obesity, Lilly could run dedicated weight-management trials (the SURMOUNT program) and market it directly to people seeking weight loss, while Mounjaro stayed focused on diabetes (the SURPASS program).

This separation also shapes pricing and access. Insurance plans frequently cover diabetes drugs more readily than weight-loss drugs, so the same person might be approved for Mounjaro but denied Zepbound, or vice versa, depending on their diagnosis. Lilly has also offered savings programs and self-pay vial options that differ between the two brands. If cost is your main concern, our breakdown of [GLP-1 savings cards for 2026](/blog/glp1-savings-cards-2026-complete-guide) walks through the current discount routes for both brands.

On tirzepatide, clinical trials show substantial weight loss that increases with dose. In the pivotal SURMOUNT-1 trial (NEJM 2022), adults with obesity and without diabetes lost a mean of 15.0% of body weight on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg over 72 weeks, compared with just 3.1% on placebo. That makes tirzepatide one of the most effective weight-loss medications studied to date.

Results differ slightly for people with type 2 diabetes, who tend to lose somewhat less, a pattern seen across GLP-1 research. The head-to-head SURMOUNT-5 trial later compared tirzepatide (Zepbound) directly against semaglutide (Wegovy) and found tirzepatide produced greater average weight loss; you can read the full results in our [SURMOUNT-5 head-to-head breakdown](/blog/surmount-5-zepbound-vs-wegovy-head-to-head-trial). Remember that trial averages are not promises: your starting weight, dose, diet, activity, and consistency all shape your individual outcome.

The biggest practical difference between Mounjaro and Zepbound is coverage, not the drug itself. Both carry a list price in the same range (roughly $1,000-$1,100 per month before insurance or discounts), but how you pay can vary widely. Because Mounjaro is a diabetes drug, plans that cover diabetes medications often approve it with a modest copay if you have a type 2 diabetes diagnosis. Zepbound is a weight-management drug, and many employer and government plans still exclude anti-obesity medications, though that is slowly changing.

Eli Lilly's self-pay program has offered lower-cost single-dose vials of Zepbound, which can make it cheaper out of pocket than you might expect. To see whether your plan is likely to pay, read our 2026 guide on [whether insurance covers GLP-1 for weight loss](/blog/does-insurance-cover-glp1-for-weight-loss-2026). The takeaway: ask your prescriber which brand your specific plan covers before you assume one is out of reach.

Yes, you can switch between Mounjaro and Zepbound without changing the actual medication, because the active drug and doses are identical. People often switch for non-medical reasons: their insurance changes, a savings program ends, one brand is in shortage, or their diagnosis shifts. When you move from one to the other at the same milligram strength, you should not need to restart the slow dose-escalation schedule, but always confirm with your prescriber.

The one thing to watch is supply and pharmacy logistics. During periods of high demand, one brand may be easier to fill than the other, and pharmacies cannot freely substitute them the way they swap generics, because they are technically different products. If you experience side effects on one, switching brands will not change them, since the molecule is the same; instead, review strategies in our guides on [managing GLP-1 nausea](/blog/glp1-nausea-why-it-happens-and-how-to-stop-it) and adjusting your dose with your clinician.

The right choice comes down to your diagnosis, your insurance, and your prescriber's guidance, not the drug's chemistry. If you have type 2 diabetes, Mounjaro is the on-label option and is most likely to be covered. If your goal is weight management or you have obstructive sleep apnea with obesity, Zepbound is the matching label. Many people qualify for one but not the other based purely on which boxes their medical chart checks.

Whatever you choose, the medication works best alongside adequate protein, resistance exercise to protect muscle, and good hydration. If you are also navigating perimenopause or menopause, hormone shifts can change how your body responds; our article on [whether GLP-1s work during menopause](/blog/do-glp1s-work-during-menopause-what-studies-show) covers what the research shows. The smartest first step is a conversation with a clinician who can match the brand to your coverage and health goals.